Press Releases PharmaTher Holdings Ltd.

Equities

PHRM

CA71716H1082

Market Closed - Canadian Securities Exchange Other stock markets 02:50:18 2024-07-12 pm EDT			5-day change	1st Jan Change
0.225 ^CAD	+2.27%		+4.65%	-28.57%

May. 15	PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine	MT
May. 10	PharmaTher Assigned FDA Approval Goal Date for its New Drug Application for Ketamine	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine	May. 15	GL
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine	May. 10	GL
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine	May. 01	GL
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	Apr. 18	GL
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	Apr. 16	GL
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia	Feb. 21	GL
CapitalGainsReport: Foreign Stocks Under .2 With Growing Potential (TBRIF, BRHCF, FFNTF, PHRRF)	Feb. 15	AQ
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	Feb. 12	GL
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	Feb. 12	AQ
PharmaTher Provides Update for Expected FDA Approval of Ketamine	Jan. 10	GL
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)	23-09-27	GL
PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA	23-09-06	GL
PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics	23-07-18	GL
PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA	23-06-27	GL
PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA	23-06-27	AQ
PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.	23-06-20	GL
PharmaTher Holdings Provides Corporate Update	23-06-12	GL
PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease	23-05-02	GL
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech	23-04-03	AQ
PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease	23-03-29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases PharmaTher Holdings Ltd.

Equities

PHRM

CA71716H1082

Press Releases

Filters